Fosamax Femur Fracture Alert: Questioning Bone Density Testing and Treatment

Share Article

Fosamax femur fractures and other side effects addressed in a New York Times article on testing and treatment options for osteoporosis, Bernstein Liebhard LLP reports.

Bernstein Liebhard LLP | Consumer Injury Lawyers
For low-risk patients with modest bone loss, or osteopenia, bisphosphonates like Fosamax and Boniva may do more harm than good.

Fosamax femur fractures and other side effects associated with bisphosphonates continue to raise questions in the medical community, Bernstein Liebhard LLP reports.* On August 27, 2012, the New York Times tackled the issue of testing and treating women for bone loss. According to the Times, the “consensus among physician groups is that healthy women who are not at any particular risk for osteoporosis should not even be tested until they turn 65.” The Times reported that earlier this year, the American Academy of Family Physicians cited bone density scans as one of five tests that are often performed unnecessarily and may lead to overtreatment of patients. Dr. Glen Stream, president of the American Academy of Family Physicians, stated “If you do testing earlier on and you identify osteopenia or osteoporosis, then you’re compelled to want to treat these folks.” He noted that, “For low-risk patients with modest bone loss, or osteopenia, bisphosphonates like Fosamax and Boniva may do more harm than good.” In May 2012, the U.S. Food and Drug Administration (“FDA”) warned that while these drugs can reduce the risk of fracture during the first few years of use, they not only have little benefit after three to five years, but also put users at risk for serious side effects such as femur fractures and osteonecrosis of the jaw.

The lawyers at Bernstein Liebhard LLP are actively filing lawsuits on behalf of individuals who allege that Fosamax caused them to sustain femur fractures in the mass tort action, In re: Fosamax Litigation (No. 282 N.J. Super Ct.), which is currently underway in the Superior Court of New Jersey, Atlantic County. The consolidated action is pending before the Honorable Carol E. Higbee.

Excessive Bone Density Testing Leads To Overprescribing Fosamax

A wave of recent studies on bisphosphonates and bone density testing has led many medical experts to reconsider treatment options, such as Fosamax. Given that Fosamax side effects are so severe, medical professionals are reevaluating when to test patients and how to make sure treatments are done only when necessary. Moreover, if a patient does, in fact, have osteoporosis, doctors are limiting the time frame that patients can take the drug. Lastly, there seems to be a shift away from using bone density measurements as a defining factor in deciding whether a woman should be treated for the disease.

Bernstein Liebhard LLP is currently representing clients and actively filing cases on behalf of individuals who were allegedly injured as a result of taking Fosamax. Those who took Fosamax and sustained a femur fracture may be entitled to compensation for medical bills, pain and suffering, lost wages and other injuries. Learn more by watching this Fosamax femur fracture video, which details the events leading up to the Fosamax lawsuits against Merck, or by visiting our website, For more information, contact a Fosamax lawyer at Bernstein Liebhard LLP today at (877) 779-1414.

*Rabin, Roni Caryn. "Many Bone Tests for Some, and Too Few for Others." New York Times 27 August 2012. The Consumer.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past nine consecutive years. Only two firms in the country have been selected for the Hot List nine years in a row.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.


Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website